TGTX TG Therapeutics Inc

TG Therapeutics, Inc. is a leading player in the multiple sclerosis therapeutics market, largely due to its drug Briumvi, which the author believes has superior efficacy compared to rival anti-CD20 monoclonal antibodies. Despite the company's increased EBIT margin, its shares have fallen, prompting the author to initiate coverage with a Buy rating. The article will delve into additional factors supporting this positive outlook.

Despite a recent 15% drop in share price, TG Therapeutics (NASDAQ:TGTX) exhibits strong financial fundamentals, particularly an impressive 74% Return on Equity (ROE) and five-year net income growth of 60%. The company's strategy of reinvesting all profits into the business, rather than paying dividends, has likely fueled this substantial growth. While future earnings growth may slow, its current performance suggests the market might be underestimating its long-term potential.

TG Therapeutics, Inc. (NASDAQ:TGTX) has received an average "Moderate Buy" rating from five brokerages, with an average one-year price target of $50.25. Recent analyst updates include JPMorgan Chase & Co. raising its target to $49 with an "overweight" rating, HC Wainwright initiating coverage with a $60 "buy" target, and B. Riley and Wall Street Zen upgrading their ratings. The company recently reported strong quarterly earnings, significantly beating estimates, and institutional investors own 58.58% of the stock.

Osaic Holdings Inc. reduced its stake in TG Therapeutics Inc. by 25.8% in Q2, selling 39,445 shares and retaining 113,345 shares valued at $4.08 million. This comes despite TG Therapeutics reporting a robust quarter with $2.43 EPS against an expected $0.24, and a 92.7% year-over-year revenue increase. Analysts maintain a "Moderate Buy" consensus with an average price target of $50.25.

TG Therapeutics (TGTX) reported Q1 earnings of $0.03 per share, missing the Zacks Consensus Estimate of $0.18, representing an 83.33% surprise. Despite the earnings miss, the biopharmaceutical company surpassed revenue estimates with $120.86 million for the quarter. The stock currently holds a Zacks Rank #3 (Hold), indicating it is expected to perform in line with the market.

Marex Group plc has made a new investment of $10.02 million in TG Therapeutics, Inc., acquiring 278,316 shares. This investment represents approximately 0.18% of TG Therapeutics, a biopharmaceutical company that recently exceeded earnings expectations with strong revenue growth. The company also holds a "Moderate Buy" consensus rating from analysts, with a target price of $50.25.